Prometheus up­sizes IPO by 33% ahead of pric­ing; Hu­mani­gen se­cures loan of up to $80M to de­vel­op lenzilum­ab

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter ini­tial­ly pen­cil­ing in a $125 mil­lion IPO …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER